Limits...
Calprotectin and platelet aggregation in patients with stable coronary artery disease.

Larsen SB, Grove EL, Pareek M, Kristensen SD, Hvas AM - PLoS ONE (2015)

Bottom Line: We performed a cross-sectional study including 581 stable, high-risk CAD patients.All patients received 75 mg aspirin daily as mono antiplatelet therapy.Compliance with aspirin was confirmed by low serum thromboxane B2 levels in all patients (median [25%;75%]: 1.07 [0.52;1.87] ng/mL).

View Article: PubMed Central - PubMed

Affiliation: Department of Cardiology, Aarhus University Hospital, DK-8200, Aarhus N, Denmark.

ABSTRACT

Background: Recent studies suggest that the inflammation-associated protein calprotectin may be implicated in the pathogenesis of coronary artery disease (CAD). However, the impact of calprotectin levels on platelet aggregation in CAD patients has never been investigated.

Objectives: We investigated the association between calprotectin levels and platelet aggregation in stable, high-risk CAD patients receiving aspirin as mono antiplatelet therapy. Furthermore, we aimed to investigate independent clinical and laboratory determinants of calprotectin levels.

Methods: We performed a cross-sectional study including 581 stable, high-risk CAD patients. All patients received 75 mg aspirin daily as mono antiplatelet therapy. Platelet aggregation was assessed by 1) impedance aggregometry (Multiplate Analyzer) using arachidonic acid (AA) and collagen as agonists and by 2) the VerifyNow Aspirin Assay. Low-grade inflammation was evaluated by calprotectin, high-sensitive C-reactive-protein (hs-CRP) and interleukin-6. Platelet activation was assessed by soluble P-selectin, and cyclooxygenase-1 inhibition was evaluated by serum thromboxane B2, both measured by ELISA.

Results: Calprotectin levels correlated positively with platelet aggregation according to Multiplate Analyzer (r=0.12, p=0.01). Additionally, calprotectin was positively associated with leukocytes (r=0.33, p<0.0001), hs-CRP (r=0.31, p<0.0001), interleukin-6 (r=0.28, p<0.0001), soluble P-selectin (r=0.10, p=0.02) and serum thromboxane B2 (r=0.10, p=0.02). Type 2 diabetes mellitus was an independent predictor of increased calprotectin levels (p=0.004), and trends were seen for body mass index (p=0.06) and smoking (p=0.07). Compliance with aspirin was confirmed by low serum thromboxane B2 levels in all patients (median [25%;75%]: 1.07 [0.52;1.87] ng/mL).

Conclusion: Calprotectin levels correlated positively, though weakly, with platelet aggregation and activation as well as serum thromboxane B2 in high-risk, stable CAD patients treated with aspirin.

No MeSH data available.


Related in: MedlinePlus

Correlation between calprotectin and serum thromboxane B2.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4430524&req=5

pone.0125992.g004: Correlation between calprotectin and serum thromboxane B2.

Mentions: Calprotectin was positively, though weakly, correlated with AA-induced platelet aggregation according to Multiplate Analyzer (Fig 1). There was no significant association between calprotectin and collagen-induced Multiplate Analyzer platelet aggregation (Fig 2) or VerifyNow (Fig 3). Calprotectin was positively associated with serum thromboxane B2 (Fig 4), sP-selectin (r = 0.10, p = 0.02), leukocytes (r = 0.33, p < 0.0001), hs-CRP (Fig 5) and IL-6 (Fig 6).


Calprotectin and platelet aggregation in patients with stable coronary artery disease.

Larsen SB, Grove EL, Pareek M, Kristensen SD, Hvas AM - PLoS ONE (2015)

Correlation between calprotectin and serum thromboxane B2.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4430524&req=5

pone.0125992.g004: Correlation between calprotectin and serum thromboxane B2.
Mentions: Calprotectin was positively, though weakly, correlated with AA-induced platelet aggregation according to Multiplate Analyzer (Fig 1). There was no significant association between calprotectin and collagen-induced Multiplate Analyzer platelet aggregation (Fig 2) or VerifyNow (Fig 3). Calprotectin was positively associated with serum thromboxane B2 (Fig 4), sP-selectin (r = 0.10, p = 0.02), leukocytes (r = 0.33, p < 0.0001), hs-CRP (Fig 5) and IL-6 (Fig 6).

Bottom Line: We performed a cross-sectional study including 581 stable, high-risk CAD patients.All patients received 75 mg aspirin daily as mono antiplatelet therapy.Compliance with aspirin was confirmed by low serum thromboxane B2 levels in all patients (median [25%;75%]: 1.07 [0.52;1.87] ng/mL).

View Article: PubMed Central - PubMed

Affiliation: Department of Cardiology, Aarhus University Hospital, DK-8200, Aarhus N, Denmark.

ABSTRACT

Background: Recent studies suggest that the inflammation-associated protein calprotectin may be implicated in the pathogenesis of coronary artery disease (CAD). However, the impact of calprotectin levels on platelet aggregation in CAD patients has never been investigated.

Objectives: We investigated the association between calprotectin levels and platelet aggregation in stable, high-risk CAD patients receiving aspirin as mono antiplatelet therapy. Furthermore, we aimed to investigate independent clinical and laboratory determinants of calprotectin levels.

Methods: We performed a cross-sectional study including 581 stable, high-risk CAD patients. All patients received 75 mg aspirin daily as mono antiplatelet therapy. Platelet aggregation was assessed by 1) impedance aggregometry (Multiplate Analyzer) using arachidonic acid (AA) and collagen as agonists and by 2) the VerifyNow Aspirin Assay. Low-grade inflammation was evaluated by calprotectin, high-sensitive C-reactive-protein (hs-CRP) and interleukin-6. Platelet activation was assessed by soluble P-selectin, and cyclooxygenase-1 inhibition was evaluated by serum thromboxane B2, both measured by ELISA.

Results: Calprotectin levels correlated positively with platelet aggregation according to Multiplate Analyzer (r=0.12, p=0.01). Additionally, calprotectin was positively associated with leukocytes (r=0.33, p<0.0001), hs-CRP (r=0.31, p<0.0001), interleukin-6 (r=0.28, p<0.0001), soluble P-selectin (r=0.10, p=0.02) and serum thromboxane B2 (r=0.10, p=0.02). Type 2 diabetes mellitus was an independent predictor of increased calprotectin levels (p=0.004), and trends were seen for body mass index (p=0.06) and smoking (p=0.07). Compliance with aspirin was confirmed by low serum thromboxane B2 levels in all patients (median [25%;75%]: 1.07 [0.52;1.87] ng/mL).

Conclusion: Calprotectin levels correlated positively, though weakly, with platelet aggregation and activation as well as serum thromboxane B2 in high-risk, stable CAD patients treated with aspirin.

No MeSH data available.


Related in: MedlinePlus